Contact
Global

Share issue
2020

Oncopeptides has completed a directed share issue raising approximately SEK 1,414 million (USD 144 M)

May 6, 2020 – Regulatory press release

Oncopeptides AB (publ) announces that the Company has successfully completed a directed share issue raising approximately SEK 1,414 million (USD 144 M) in gross proceeds.

The board of directors of Oncopeptides has, based on the issue authorization granted by the extraordinary general meeting on December 17, 2019, and as indicated in the Company’s press release on May 5, 2020, resolved on a directed share issue of 12,295,000 new shares (the “New Shares”) at a subscription price of SEK 115 per share (the “Directed Share Issue”), which means that the Company will receive gross proceeds of approximately SEK 1,414 million (approximately USD 144 million). Due to high demand, the gross proceeds in the Directed Share Issue were increased from the SEK 1,180 million indicated in the Company’s press release on May 5, 2020.

Read the press release

Oncopeptides intends to carry out a directed share issue

May 5, 2020 – Regulatory press release Oncopeptides AB (publ) announces its intention to carry out a directed share issue to Swedish and international institutional investors (the “Directed Share Issue”). The Company has retained Carnegie, DNB Markets, Jefferies, Cowen and Kempen & Co to act as Joint Bookrunners (the “Joint Bookrunners”) in connection with the Directed Share Issue. The subscription price and the total number of new shares in the Directed Share Issue will be determined by way of an accelerated bookbuild process (the “Bookbuilding”). It is intended that approximately SEK 1,180 million (USD 120 million) in gross proceeds will be raised from the Directed Share Issue. Bookbuilding will start immediately following this announcement.
Read the press release

On this page

Select language or region
Language
Region
Global

Learn more about the company Oncopeptides and the work we do to redefine cancer care

Our science
Pepaxti®

Learn more about the company Oncopeptides and the work we do to redefine cancer care

About us

Learn more about the company Oncopeptides and the work we do to redefine cancer care

For investors

Learn more about the company Oncopeptides and the work we do to redefine cancer care

Our newsroom
Contact
Global
Disclaimer

I am located in a country where access to this information is permitted and not in any of the countries where publication is unlawful or requires special approval (e.g. the United States, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa or South Korea).

I cannot confirm
I confirm

Not sure if you can access the content? Click here to read the full terms.